Bionano's Q2 2026: Record Flow Cell Sales and Gross Margin Signal a Turning Point

Clinical adoption drives consumable growth, while supply constraints temper guidance

BNGO · Earnings Call · 2026-08-10

A Strong Quarter, Backed by Clinical Adoption

Bionano Genomics reported a second quarter that, by its own standards, is nothing short of a milestone. Revenue came in at $8.2M, up 21% year-over-year and above the guidance range of $7.5‑$7.8M. The headline driver is the record flow cells sold — 9,220 units, up 27% YoY — and management attributes this directly to clinical adoption. As interim CEO Albert A. Luderer put it in his prepared remarks: “The growth of our consumable sales this quarter was primarily driven by increased clinical adoption.” — Albert A. Luderer, Chairman and Interim CEO · 2026-08-10 That adoption is not just U.S.‑centric; international revenue now represents the majority of total revenue, with leading European institutions leading the charge. The increase utilization among existing customers is the engine — management explicitly noted that the majority of growth comes from existing clients rather than new placements. This aligns with the strategic pivot initiated in September 2024 to focus on routine users instead of aggressive installed‑base expansion. The OGM system installed base grew 5% to 397, but flow cells sold per system accelerated sharply — a sign that the installed base is being monetized more efficiently. The contrast with prior quarters is stark: in Q1 2026, the company had to explain why consumable sales were essentially flat; now they're up double digits.

Reimbursement and the Path to Profitability

The reimbursement catalyst that has been building for over a year is finally translating into tangible demand. The two Category I CPT codes covering OGM in hematologic malignancies ($1,850) and constitutional genetic disorders ($1,260) took effect in January 2026, and management sees them now “starting to drive the sales.” In the Q&A, Luderer elaborated:

We are very much constrained in terms of our flow cell manufacturing capacity... we are reluctant to raise the top line until we know for certain that our manufacturing can keep up with demand.
Albert A. Luderer, Chairman and Interim CEO · 2026-08-10

That supply constraint is the main reason full‑year guidance was only partially raised (to $31‑$33M, from $30‑$33M), even though Q2 beat. Management expects manufacturing capacity to improve by mid‑to‑late Q4, which would allow them to fully satisfy demand. Meanwhile, profitability is improving. Adjusted gross margin reached 53%, the highest ever, up from 52% a year ago and consistent with the multi‑year upward trajectory in Gross Margin. Operating expenses were essentially flat at $8.7M. The company fully retired its senior secured convertible debt during the quarter, simplifying the balance sheet and reducing interest burden.

This progress stands in contrast to management’s tone just a quarter ago. In the May 2026 call, Principal Accounting Officer Mark Adamchak said: “No, we do not expect to reach cash flow breakeven by the end of 2026.” — Mark Adamchak, Vice President of Accounting and Principal Accounting Officer · 2026-05-13 Now the company is clearly moving closer, though still not guiding to breakeven. The combination of higher gross margins, flat opex, and revenue growth is narrowing the path.

Supply Constraints and the Road Ahead

While the operational momentum is real, the supply bottleneck is the key near‑term variable. The company is essentially selling as many flow cells as it can make. In the Q&A, Luderer noted that the majority of growth comes from existing clients and that demand remains “tremendous.” However, the Q3 guidance of $8.2‑$8.6M implies only modest sequential growth, with management citing “several very large orders that are very close to the end of the third quarter” as a reason for conservatism. This is not a story of fading demand — it's a story of manufacturing catching up. Investors should watch whether the company can add capacity without diluting margins. The recent hiring of Dr. Alex Hastie as Chief Scientific Officer (one of the original architects of the OGM technology) signals a commitment to scientific leadership and menu expansion, which could further drive utilization. The stock, though down ~98% from its 2021 peak, has been flat to slightly up over the past 90 days (+6.2%). At a market cap of just $14M, the company is priced for failure; any sustained execution on the revenue and margin front could re‑rate the shares. But the balance sheet remains fragile — effective net cash of $25M, and a cash runway extending at least into Q1 2027. The company is still loss‑making, with Q2 net income of −$8M. Still, the evidence from this quarter — record flow cell sales, record gross margin, debt retirement, and a raised guidance floor — suggests that the strategic pivot is working. The next two quarters will be critical to confirm that the supply constraint can be resolved and that the clinical adoption trend is durable. If it is, Bionano could finally be on the path it has promised investors since 2024.